MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting.

By integrating methylation signatures (epigenetic signatures) into its whole-genome platform, MyOme is moving beyond traditional DNA sequencing to resolve complex cases that contribute to an average five-year diagnostic delay for rare disease patients.1,2 Recent meta-analyses confirm that a genome-first approach significantly increases diagnostic yield and clinical utility over legacy exome methods, providing the foundation for MyOme's multi-omic innovations.3

Natera Launches Zenith Powered by MyOme

In a major step toward expanding patient access, MyOme highlighted its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith powered by MyOme. Zenith is a premium exome and genome testing solution that brings MyOme's genome-first platform to Natera's clinical network.

The Zenith portfolio is available for commercial orders through Natera, bringing Zenith genomics to healthcare providers across the United States by leveraging Natera's extensive electronic medical record integration footprint, clinical support system, and high-complexity genomics experience.

"Rare disease patients and their families endure lengthy and costly diagnostic journeys that often delay care and escalate emotional and financial strain," said Meredith Reichert, Ph.D., senior vice president of commercial and general manager of rare disease at Natera. "By combining MyOme's innovation with Natera's nationwide presence and clinical expertise, Zenith has the potential to transform rare disease diagnostics and provide definitive answers to more families."

The Methylation Advantage

Traditional genetic testing identifies changes in DNA sequence but requires separate testing to evaluate epigenetic modifications that influence gene expression. MyOme's new multi-omic approach leverages long-read sequencing to simultaneously analyze DNA sequence and methylation patterns and identify disease-related epigenetic signatures.

At launch, MyOme will perform targeted confirmation for select conditions, with a roadmap to rapidly expand the disease areas available on the platform. This capability allows clinicians to:

1. Resolve variants of uncertain significance when a methylation signature is available for a gene
2. Assist in resolving imprinting conditions when parental samples are missing

"It is increasingly clear that the next frontier in addressing rare diseases involves probing genome function alongside sequence," said Akash Kumar, M.D., Ph.D., chief medical officer at MyOme. "By introducing methylation analysis using long-read sequencing, we are taking an important step for comprehensiveness -- one that can detect what standard sequencing approaches might miss on their own."4

Starting in early Q2 2026, methylation analysis will be automatically integrated into all eligible rare disease exome and genome analysis orders.

ACMG 2026 Highlights

MyOme's presence at ACMG 2026 underscored its commitment to the medical genetics community.

Scientific poster:

• P207: Development of a Single Sequencing Platform for Variant Detection and Methylation Characterization

For more information, visit myome.com/landing/myome-at-acmg.

About MyOme

MyOme is a clinical whole genome analysis company helping families understand their risk for diseases. As a leader in polygenic and AI-based integrative risk modeling, MyOme leverages the power of whole genome, multianalyte, and clinical data for a lifetime of meaningful and actionable insights. These capabilities can reduce healthcare costs and improve outcomes by identifying disease risk earlier and enabling preventive interventions.

Certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP), MyOme is based in Menlo Park, California.

References

1. Community Leadership: MyOme is the official sponsor of Medical Genetics Awareness Week (March 10-14), supporting the theme "Making a Difference Together."
2. The Global Commission to End the Diagnostic Odyssey for Children with a Rare Disease. "From Idea to Action: 2024 End of Year Report." https://globalrarediseasecommission.com/pressrelease-2024eoyreport/
3. Pandey R, et al. A meta-analysis of diagnostic yield and clinical utility of genome and exome sequencing in pediatric rare and undiagnosed genetic diseases (2025).
4. Negi et al. Advancing long-read genome assembly and accurate variant calling for rare disease detection. American Journal of Human Genetics (2025).